Skip to main content

Table 1 Patients and tumour characteristics

From: Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound

Age (years)

Median 62 (31–79)

Menopausal status pre/post

25/64

pT stage

 

pTis

12

pT1

66

pT2 (≤3 cm)

11

pN stage

 

pN0

70

pN1 (≤ 3 positive nodes)

19

Estrogen receptor status

 

Positive/negative

76/13

Progesteron receptor status

 

Positive/negative

76/13

Chemotherapy yes/no

36/53

Hormonotherapy

 

No

20

Tamoxifen

35

Anastrozole

18

Letrozole

16

Follow-up (months)

20.5 (11.4-85.7)